Recently, the US Food and Drug Administration's (FDA) Center for Tobacco Products (CTP) awarded two grants to Dr. Tracy Smith at the Hollings Cancer Center at MUSC for researching the potential impact of allowing flavored e-cigarettes and banning the use of menthol.
This move has been welcomed by global tobacco harm reduction (THR) experts who have long urged the FDA to study the scientific basis of such products.
Smith said:
The FDA has the authority to do many things that can greatly assist in improving public health and reducing preventable diseases caused by smoking.
She will collaborate with Dr. Theodore Wagener, the director of the Tobacco Research Center at the Ohio State University Comprehensive Cancer Center, to conduct a $3.9 million research study on the flavors of electronic cigarettes.
Wagner stated that so far, any regulatory decisions made by the FDA have been based on incomplete scientific data.
He added that this would be the first study to provide the organization with authoritative information regarding whether the product is beneficial to adult smokers.
References:
A researcher at Hollings is examining the impact of menthol and e-cigarette flavors on current cigarette smokers.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
